Stock Analysis

Heren HealthLtd (SZSE:300550) investors are up 10% in the past week, but earnings have declined over the last three years

SZSE:300550
Source: Shutterstock

By buying an index fund, investors can approximate the average market return. But if you buy good businesses at attractive prices, your portfolio returns could exceed the average market return. For example, Heren Health Co.,Ltd. (SZSE:300550) shareholders have seen the share price rise 23% over three years, well in excess of the market decline (14%, not including dividends). On the other hand, the returns haven't been quite so good recently, with shareholders up just 12%, including dividends.

The past week has proven to be lucrative for Heren HealthLtd investors, so let's see if fundamentals drove the company's three-year performance.

View our latest analysis for Heren HealthLtd

In his essay The Superinvestors of Graham-and-Doddsville Warren Buffett described how share prices do not always rationally reflect the value of a business. One way to examine how market sentiment has changed over time is to look at the interaction between a company's share price and its earnings per share (EPS).

During three years of share price growth, Heren HealthLtd moved from a loss to profitability. So we would expect a higher share price over the period.

You can see how EPS has changed over time in the image below (click on the chart to see the exact values).

earnings-per-share-growth
SZSE:300550 Earnings Per Share Growth January 27th 2025

Before buying or selling a stock, we always recommend a close examination of historic growth trends, available here.

A Different Perspective

Heren HealthLtd provided a TSR of 12% over the last twelve months. But that return falls short of the market. The silver lining is that the gain was actually better than the average annual return of 2% per year over five year. This could indicate that the company is winning over new investors, as it pursues its strategy. It's always interesting to track share price performance over the longer term. But to understand Heren HealthLtd better, we need to consider many other factors. For instance, we've identified 1 warning sign for Heren HealthLtd that you should be aware of.

Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of companies we expect will grow earnings.

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on Chinese exchanges.

Valuation is complex, but we're here to simplify it.

Discover if Heren HealthLtd might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.

Access Free Analysis

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

About SZSE:300550

Heren HealthLtd

Provides medical solutions to hospitals and governments in China.

Flawless balance sheet with questionable track record.

Community Narratives

Top Pick for Multi-bagger
Fair Value US$44.06|48.162% undervalued
SuEric
SuEric
Community Contributor
Nova Ljubljanska Banka d.d will expect a 11.2% revenue boost driving future growth
Fair Value €148.18|9.9069% undervalued
AurediusCapital
AurediusCapital
Community Contributor